What was the market valuation of the US obesity management market in 2024?

The market valuation was $871.5 Million in 2024. Read More

What is the projected market valuation for the US obesity management market in 2035?

The projected market valuation for 2035 is $1784.1 Million. Read More

What is the expected CAGR for the US obesity management market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.73%. Read More

Which companies are considered key players in the US obesity management market?

Key players include Novo Nordisk, Bristol-Myers Squibb, Amgen, Eli Lilly and Company, Pfizer, Sanofi, GSK, Merck & Co., and AstraZeneca. Read More

What are the main segments of the US obesity management market?

The main segments include Type, End User, Treatment Method, and Distribution Channel. Read More

What was the valuation range for surgical procedures in the US obesity management market?

The valuation range for surgical procedures was $200.0 Million to $400.0 Million. Read More

How much did the pharmacotherapy segment contribute to the market in 2024?

The pharmacotherapy segment contributed between $250.0 Million and $500.0 Million. Read More

What is the projected valuation for fitness programs in the US obesity management market?

The projected valuation for fitness programs ranges from $121.5 Million to $284.1 Million. Read More

What is the valuation range for hospitals as an end user in the market?

The valuation range for hospitals as an end user is between $300.0 Million and $600.0 Million. Read More

What is the expected growth trend for the pharmaceuticals segment in the US obesity management market?

The pharmaceuticals segment is expected to grow, with a valuation range of $300.0 Million to $600.0 Million. Read More

US Obesity Management Market

ID: MRFR/Pharma/16774-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Obesity Management Market Research Report: Size, Share, Trend Analysis By Types (Surgical Procedures, Pharmacotherapy, Lifestyle Changes, Fitness Programs), By End Users (Clinics, Hospitals, Home Care, Fitness Centers), By Treatment Method (Bariatric Surgery, Pharmaceuticals, Nutritional Counseling, Behavioral Therapy) and By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospitals, Direct Sales) - Growth Outlook & Industry Forecast 2025 To 2035

US Obesity Management Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Surgical Procedures
  2. 4.1.2 Pharmacotherapy
  3. 4.1.3 Lifestyle Changes
  4. 4.1.4 Fitness Programs
2. 4.2 Pharmaceutical, BY End User (USD Million)
  1. 4.2.1 Clinics
  2. 4.2.2 Hospitals
  3. 4.2.3 Home Care
  4. 4.2.4 Fitness Centers
3. 4.3 Pharmaceutical, BY Treatment Method (USD Million)
  1. 4.3.1 Bariatric Surgery
  2. 4.3.2 Pharmaceuticals
  3. 4.3.3 Nutritional Counseling
  4. 4.3.4 Behavioral Therapy
4. 4.4 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.4.1 Online Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Hospitals
  4. 4.4.4 Direct Sales
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novo Nordisk (DK)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Eli Lilly and Company (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GSK (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY END USER
4. 6.4 US MARKET ANALYSIS BY TREATMENT METHOD
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY TREATMENT METHOD, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY TREATMENT METHOD, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY END USER, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT METHOD, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

Surgical Procedures
Pharmacotherapy
Lifestyle Changes
Fitness Programs

Pharmaceutical By End User (USD Million, 2025-2035)

Clinics
Hospitals
Home Care
Fitness Centers

Pharmaceutical By Treatment Method (USD Million, 2025-2035)

Bariatric Surgery
Pharmaceuticals
Nutritional Counseling
Behavioral Therapy

Pharmaceutical By Distribution Channel (USD Million, 2025-2035)

Online Pharmacies
Retail Pharmacies
Hospitals
Direct Sales

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”